ACTIVE

OMEGA PHARMA INNOVATION & DEVELOPMENT

Financial year 2025 · Closed on 31/12/2025

Net result11,4 M €+16,7 %over 1 year
Revenue16,3 M €-70,4 %over 1 year
Equity240,2 M €+92,7 %over 1 year
Workforce38,2 ETP-11,4 %over 1 year

Identity

Source · BCE/KBO

OMEGA PHARMA INNOVATION & DEVELOPMENT is a Public limited company incorporated in 2006. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Gent. It employs on average 38,2 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0884.084.724
Incorporation
09/10/2006
Legal form
Public limited company
Registered office
Gaston Crommenlaan 6 box 606
9050 Gent · FlandreSee on map
Contributed capital
123 392 195,00 €
Latest accounts
31/12/2025
Average workforce
38,2 ETP
Joint committees (2)
  • 207
  • 218
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debtsHigh revenue

Financials

Source · NBB, 19 filings

Trend over 17 financial years

20252023202220212020
Income statement
Revenue16,3 M €55,2 M €49,1 M €44,7 M €44,1 M €
EBITDA997 k €21 M €17,4 M €11,2 M €-187,3 M €
Operating result-545,8 k €9 M €2,2 M €-4,8 M €-227,5 M €
Net result11,4 M €9,7 M €2 M €-9,9 M €-186,1 M €
Balance sheet
Equity240,2 M €124,6 M €123,4 M €121,4 M €274,8 M €
Total assets246,6 M €152,8 M €145,7 M €141,9 M €356,7 M €
Cash7,2 k €1,8 k €1,8 k €1,8 k €1,8 k €
Debts6,4 M €28 M €19,9 M €19,9 M €80,3 M €
Other
Workforce38,2 ETP43,1 ETP44,5 ETP46,7 ETP47,0 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 100 M€ and 250 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

4 active · 15 ended

Active mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Jonas Dhaenens
Director22/05/2026 → 13/05/2032
Sonia Hollies
Director29/08/2024 → 09/05/2030
Magali Verbraeken
Director23/01/2023 → 22/01/2029
Anja van Winsberghe
Director17/05/2021 → 13/05/2027

Ended mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Mira De Maeyer
Directorlisted until the 2023 accounts
Gianluca Parola
Director29/07/2021 → 2022 accounts
PACHTERSBOS0846.277.389Represented by Lieven Costers
Director01/01/2020 → 31/12/2023

Other companies at this address

Gaston Crommenlaan 6 9050 Gent
CompanyCBE no.
BRAVX● Active
0834.939.871
0676.420.293
Oce-Bio● Active
0442.861.022
0837.048.632
0807.596.363
0417.092.080
Perrigo Belgium● Active
0417.132.860
Perrigo Capital● Active
0430.784.027
0439.658.834
Perrigo Holding● Active
0431.676.229
Silverfin● Active
0524.802.662
0787.232.501
1008.974.796
TM Goedingebrug● Active
1039.143.281
1035.016.328

Full financial information

Source · NBB
202520242023202220212020
Type of accountFull modelFull modelFull modelFull modelFull modelFull model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date07/07/202618/06/202522/05/202425/05/202317/06/202214/06/2021
General meeting29/06/202620/05/202513/05/202411/05/202312/05/202217/05/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 19 filings
ModelClosingGeneral meetingFiledLanguageDocument
Full model31/12/202529/06/202607/07/2026DutchPDF
Full model31/12/202420/05/202518/06/2025DutchPDF
Full model31/12/202313/05/202422/05/2024DutchPDF
Full model31/12/202211/05/202325/05/2023DutchPDF
Full model31/12/202112/05/202217/06/2022DutchPDF
Full model31/12/202017/05/202114/06/2021DutchPDF
Full model31/12/201914/05/202011/06/2020DutchPDF
Full model31/12/201809/05/201927/05/2019DutchPDF
Full model31/12/201718/06/201822/06/2018DutchPDF
Full model31/12/201629/09/201714/11/2017DutchPDF
Full model31/12/201530/06/201615/07/2016DutchPDF
Full model31/12/201415/06/201519/06/2015DutchPDF
Full model31/12/201316/06/201424/06/2014DutchPDF
Full model31/12/201217/06/201326/06/2013DutchPDF
Full model31/12/201118/06/201216/07/2012DutchPDF
Abridged model31/12/201020/06/201128/07/2011FrenchPDF
Abridged model31/03/201017/09/201030/09/2010FrenchPDF
Abridged model31/03/200918/09/200930/10/2009FrenchPDF
Abridged model31/03/200802/02/200914/04/2009FrenchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 100 M€ and 250 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

4 active · 15 ended

Active mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Jonas Dhaenens
Director22/05/2026 → 13/05/2032
Sonia Hollies
Director29/08/2024 → 09/05/2030
Magali Verbraeken
Director23/01/2023 → 22/01/2029
Anja van Winsberghe
Director17/05/2021 → 13/05/2027

Ended mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Mira De Maeyer
Directorlisted until the 2023 accounts
Gianluca Parola
Director29/07/2021 → 2022 accounts
PACHTERSBOS0846.277.389Represented by Lieven Costers
Director01/01/2020 → 31/12/2023

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Mandates08/06/2026
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates22/12/2025
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates15/10/2024
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates18/06/2024
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Registered office15/03/2024
    MAATSCHAPPELIJKE ZETEL
    PDF
  • Mandates07/03/2024
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates01/03/2023
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates05/01/2023
    ONTSLAGEN - BENOEMINGEN
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts
Year
Identity
Incorporation
Name
Registered office
Annual accounts
Filings17 filings
Mandates
Jonas Dhaenens
Sonia Hollies
Magali Verbraeken
Anja van Winsberghe
Mira De Maeyer
Gianluca Parola
PACHTERSBOS
Patrick O'Sullivan
BRANDRACER
Griet Vandenheede
AUBISQUE
ADN Innovative Solutions
200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032
OMEGA PHARMA INNOVATION & DEVELOPMENTlaboratoires DUHOT
Gaston Crommenlaan 6 bte 606, 9050 Ledeberg (Gent)Venecoweg 26, 9810 Nazareth-De Pinte
Director
Director
Director
Director
Director
Director
Director
Director
Director
Director
CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE
Registered addressPeriodSource
Gaston Crommenlaan 6 bte 606, 9050 Ledeberg (Gent)Current
accounts 2023 → 2025
Accounts 2025 · 2026-00276458
Venecoweg 26, 9810 Nazareth-De Pinte
accounts 2021 → 2022
Accounts 2022 · 2023-00100902

Company names

Source · NBB annual accounts, CBE
NamePeriodSource
OMEGA PHARMA INNOVATION & DEVELOPMENTCurrent
accounts 2011 → 2025
Accounts 2025 · 2026-00276458
laboratoires DUHOT
accounts 2008 → 2010
Accounts 2010 · 2011-35000115

Events

  1. 22/05/2026
    nominationJonas Dhaenens · bestuurder
  2. 2025
    Annual accounts 202511,4 M €↑
  3. 20/05/2025
    nominationBDO Bedrijfsrevisoren BV · commissaris
  4. 29/08/2024
    nominationSonia Hollies · bestuurder
  5. 13/05/2024
    reconductionPaul Eelen · commissaris
  6. 01/01/2024
    nominationMira De Maeyer · bestuurder
  7. 2023
    Annual accounts 20239,7 M €↑
  8. 23/01/2023
    nominationMagali Verbraeken · bestuurder
  9. 2022
    Annual accounts 20222 M €↑
  10. 2021
    Annual accounts 2021-9,9 M €↑
  11. 2020
    Annual accounts 2020-186,1 M €↓
  12. 2019
    Annual accounts 2019-45,5 M €↓
  13. 2018
    Annual accounts 2018-28,6 M €↓
  14. 2017
    Annual accounts 2017-7,1 M €↑
  15. 2016
    Annual accounts 2016-142,5 M €↓
  16. 2015
    Annual accounts 2015-32,3 M €↓
  17. 2014
    Annual accounts 20147,7 M €↑
  18. 2012
    Annual accounts 2012-1,7 M €↓
  19. 2011
    Annual accounts 2011977,2 k €↑
  20. 2011
    Name changeOMEGA PHARMA INNOVATION & DEVELOPMENT
  21. 2010
    Annual accounts 2010742,3 k €↓
  22. 2010
    Annual accounts 2010803,6 k €↑
  23. 2009
    Annual accounts 2009160,5 k €↓
  24. 2008
    Annual accounts 2008589,1 k €
  25. 09/10/2006
    IncorporationPublic limited company